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asthma are at risk of frequent disease exacerba‑
tions resulting from exposure to allergens, pol‑
lutants, viral infections, certain drugs, or oth‑
er triggers.7
There are 2 primary types of asthma: T ‑helper 
cell type 2 (Th2)‑driven (or in a wider sense, type 
2 ‑driven) and non–Th2 ‑driven (or in a broader 
sense, non–type 2 ‑driven). Type 2 ‑driven asth‑
ma is often triggered by allergens like pollens, 
house dust mite (HDM) or animal dander, where‑
as non–type 2 ‑driven asthma may be caused by 
airway infections, smoking, obesity, or other 
irritants.7,8 Several type 2 ‑driven phenotypes 
have been reported by different authors, includ‑
ing early ‑onset allergic, late ‑onset eosinophilic, 
and exercise ‑induced asthma, which have been 
most consistently described. Obesity ‑associated 
Introduction In recent decades, a significant in‑
crease in asthma incidence has been observed, 
especially in industrialized countries.1,2 Asthma 
is a widespread chronic inflammatory disease, 
which has a highly heterogeneous pathogenesis 
and clinical picture.3,4 Asthma has been defined 
by the National Heart, Lung, and Blood Institute 
as a “common chronic disorder of the airways that 
is complex and characterized by variable and re‑
curring symptoms, airflow obstruction, bronchial 
hyperresponsiveness, and an underlying inflam‑
mation”.5 General symptoms include coughing, 
wheezing, or shortness of breath.5,6 Asthma may 
be also accompanied by comorbidites, such as al‑
lergic rhinitis, atopic dermatitis, and food aller‑
gy, or nonallergic disorders like obesity and gas‑
troesophageal reflux. Furthermore, patients with 
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ABSTRACT
Asthma is a widespread chronic inflammatory disease, which has a highly heterogeneous etiopatho‑
genesis, with predominance of either T ‑helper cell type 2 (Th2; type 2) or non–Th2 (non–type 2) mecha‑
nisms. Together with cardiovascular or autoimmune diseases, obesity, and others, asthma belongs to 
so called noncommunicable diseases, a group of disorders with immunometabolic links as underlying 
mechanisms. So far, obesity and asthma have been considered mostly independently, but there are 
clear signs of relevant interactions. First, obese patients are at increased risk of asthma or asthma ‑like 
symptoms. Second, asthma accompanied by obesity is more severe and more difficult to treat. A specific 
phenotype called obesity ‑associated asthma has been also described, which is late ‑onset, rather severe, 
non–type 2 ‑driven disease, present mostly in women. In addition, obesity can coincide with asthma 
also in children, and, although obesity generally skews the Th1/Th2 balance towards Th1, it can also 
accompany type 2 ‑driven asthma. However, those combinations represent less precisely defined disease 
entities. Despite a substantial increase in our knowledge on the mechanisms mediating the effects of 
obesity on the development of asthma in several recent years, still much needs to be done, especially 
on the molecular level.
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test for the identification of atopic asthma at a 
young age is available.3 Still, several of its char‑
acteristics have been rather uniformly described 
(FIGURE 1).3,9,10 Early ‑onset asthma is frequent‑
ly accompanied by other atopic diseases typical 
for childhood, such as allergic rhinitis or atopic 
dermatitis.9 Adult ‑onset eosinophilic asthma, as 
the name suggests, is defined by an increase of eo‑
sinophils determined by sputum or blood analy‑
sis, or bronchoscopy, and it first appears in adult‑
hood.9 This phenotype is often accompanied or 
preceded by chronic sinusitis and nasal polyps and 
tends to be characterized by severe disease onset 
(FIGURE 1).3,9 Little is known about the immunolo‑
gy of exercise ‑induced asthma. The typical symp‑
toms occur after exercise, with patients showing 
mild asthma symptoms and suffering from reac‑
tive bronchoconstriction (FIGURE 1).9
Non–type 2 ‑driven asthma There is still no con‑
sensus as to whether non–type 2 ‑driven asth‑
ma ought to be considered as a single mecha‑
nistic entity or if it should be rather subdivid‑
ed into several more specific endotypes (ie, dis‑
ease subtypes functionally and pathologically de‑
fined by molecular mechanisms and treatment 
responses), possibly in close relation to the clin‑
ical characteristics or phenotypes, for example, 
postviral AHR or neutrophilic inflammation due 
to smoking.3,17,18 The term “non–type 2 ‑driven 
asthma” has been created somewhat in contrast 
to type 2 ‑driven asthma; therefore, it partly cov‑
ers so far unidentified and possibly more hetero‑
geneous disease mechanisms sharing the fea‑
ture of simply not being type 2 ‑related. Since 
there is limited knowledge on the connection 
between clinical conditions, response to thera‑
py, and pathology, such as the contribution of 
and neutrophilic (smoke ‑related) asthma are in 
turn the major non–type 2 ‑driven phenotypes 
(FIGURE 1).3,7,9,10
Types of asthma Type 2 ‑driven asthma Type 
2 ‑driven asthma is defined by the presence of 
atopic sensitization, immediate hypersensitivi‑
ty type of allergic reaction, eosinophilic inflam‑
mation, and responsiveness to corticosteroids.9 
Th2 or innate lymphoid cells type 2 (ILC2s) and 
the cytokines they produce, such as interleukin 
(IL)‑4, IL ‑5, and IL ‑13, play a crucial mechanistic 
role here. They stimulate allergic and eosinophil‑
ic inflammation, which further leads to changes 
in the epithelial and smooth muscle cells, result‑
ing in hyperproduction of mucus, higher smooth 
muscle contractility, and airway hyperrespon‑
siveness (AHR).11,12 These cytokines induce dif‑
ferentiation from naive T ‑cells to Th2 cells and 
(especially IL ‑4, but also IL ‑13) stimulate B ‑cell 
switch towards immunoglobulin E (IgE) produc‑
tion, thus increasing IgE synthesis. The activa‑
tion of eosinophils is in turn triggered by IL ‑5, 
whereas IL ‑13 induces AHR and enhanced mucus 
production.11‑15 The type 2 mechanisms underlie 
the disease of various levels of severity, ranging 
from mild through moderate to severe and show‑
ing different responses to treatment.10 However, 
type 2 asthma is typically associated with a ro‑
bust response to inhaled corticosteroids.16 Sev‑
eral phenotypes of type 2 asthma have been de‑
scribed, as mentioned above (FIGURE 1).3,7,9,10 Al‑
though in atopic asthma, sensitization to environ‑
mental allergens occurs and there is a clear cor‑
relation between allergen exposure and asthma 
symptoms,8 it is rather difficult to precisely de‑
fine early ‑onset allergic asthma, since no specific 
cutoff age has been determined nor an effective 
Non–type 2-driven asthma 
Early-onset allergic asthma
early onset, mild-to-severe,
allergic symptoms, other allergies 
IgE, Th2 cytokines
CS responsive
Clinics: late onset, frequently severe, allergy less
pronounced 
eosinophils, IL-5
Therapy: 
Clinics: 
Mechanism/
biomarkers: 
Clinics: 
Therapy: 
anti–IL-5-antibody responsive, CS resistant
Exercise-induced asthma 
mild, triggered by exercise 
mast cells, Th2 cytokines
β-agonists and anti–IL-9 antibody
responsive
Neutrophilic asthma
Clinics: low FEV1, more air trapping 
Mechanism/
biomarkers: sputum neutrophils, IL-17 responses
Therapy: 
Clinics: 
Mechanism/
biomarkers: 
Therapy: 
macrolides?
late onset, mostly women
no Th2 responses, oxidative stress
weight loss responsive, CS resistant  
Adult- (late-)onset eosinophilic asthma 
Type 2-driven asthma
Obesity-associated asthma
Mechanism/
biomarkers:
Mechanism/
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Therapy: 
FIGURE 1  Basic 
characteristics of the 
major phenotypes of type 
2‑driven and non–type 
2‑driven asthma3,7,9,10 
Abbreviations: IgE, 
immunoglobulin E; CS, 
corticosteroids; IL, 
interleukin; FEV1, forced 
expiratory volume in 
1 second; Th2, T‑helper 2
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in almost half of the Europeans (47.6%) and obe‑
sity, in 12.8%.22 The latter results in chronic low‑
‑grade systemic inflammation due to the produc‑
tion of inflammatory mediators in adipose tissue, 
described in more detail below.23 This effect can 
add to chronic systemic inflammation observed in 
asthma, which presumably results in a further in‑
crease in susceptibility to airway obstruction and 
nonspecific AHR.23 The clinical picture of asthma 
associated with obesity is typically characterized 
by poor quality of life, aggravation of daily symp‑
toms (mostly severe), and a frequent use of res‑
cue medications.24,25 Besides the severe clinical 
characteristics, several comorbidities of obesity 
may also occur. Conditions classically accompany‑
ing obesity, such as gastroesophageal reflux dis‑
ease, sleep ‑disordered breathing, dyslipidemia, 
type 2 diabetes mellitus, or hypertension, may 
not only increase the risk of asthma but also ag‑
gravate the disease if already present.26 Some of 
the effects of obesity on asthma are rather me‑
chanical, whereas some others seem to be under‑
lying the enhancement of asthma ‑associated in‑
flammation due to increased (unbalanced) pro‑
duction of proinflammatory mediators (adipo‑
kines) in overgrown, inflamed, and dysregulated 
fat tissue (FIGURES 2 and 3). This leads to further al‑
terations in immune responses, including an in‑
creased synthesis of inflammatory cytokines: not 
only TNF ‑α or IL ‑6, at least partly derived from 
fat tissue and thus considered also as adipokines, 
but also IFN ‑γ and IL ‑17.9,11,27 However, the com‑
plete mechanism behind the contribution of obese 
adipose tissue to the development and clinical 
course of asthma has not been fully elucidated.
As indicated above, the clinical and mechanis‑
tic complexity of asthma associated with obesi‑
ty seems to go far beyond the distinct obesity‑
‑associated asthma phenotype, as briefly depicted 
in FIGURE 1. Although this classic obesity ‑associated 
asthma is related to non–type 2 inflammatory 
processes, other types like type 2 ‑driven inflam‑
matory asthma in obese patients and asthma in 
obese children, have also been described.9,28 Hol‑
guin et al25 reported differential effects of obesi‑
ty on asthma in adults depending on the age of 
onset. Obese patients with early age at onset had 
greater AHR, more severe airway obstruction, 
and a higher exacerbation risk compared with 
obese patients with late age at onset. Moreover, 
they were characterized by more advanced ato‑
py with higher serum IgE levels and less severe 
eosinophilic inflammation. Finally, in early‑ but 
neutrophils, the distinction between such en‑
dotypes of non–type 2 ‑driven asthma would be 
difficult, as it sometimes is even between type 
2 ‑driven phenotypes. Different factors, such as 
cigarette smoke or obesity, can lead to dysregu‑
lated innate immune responses in the airways, 
with no history of type 2 ‑driven asthma during 
childhood.3 The activation of Th17 pathways and 
Th1 immunity in combination with metabolic in‑
fluences contribute to non–type 2 ‑driven asth‑
ma. Interferon γ (IFN ‑γ), tumor necrosis factor α 
(TNF ‑α), and IL ‑17, which are typical Th1 (type 1) 
or Th17 cytokines, promote neutrophilic inflam‑
mation.19,20 There are only limited therapeutic op‑
tions available in non–type 2 ‑driven asthma be‑
cause, unlike type 2 ‑driven disease, it tends to 
be refractory to corticosteroid treatment.16 Two 
non–type 2 ‑driven phenotypes have been de‑
scribed most coherently (FIGURE 1).3,7,9,10 The neu‑
trophilic asthma phenotype is characterized by 
increased neutrophil count in peripheral blood, 
lungs, and sputum, and neutrophilia often devel‑
ops after chronic steroid use or smoking.3 This 
subphenotype is not characterized by AHR; rath‑
er, the signs typical of neutrophilic asthma in‑
clude reduced lung function, more air trapping, 
and thicker airway walls (FIGURE 1).9 In turn, lack 
of atopy, late onset, and female predominance are 
characteristic for the obesity ‑associated asthma 
phenotype.3 The symptoms resulting from the ac‑
companying obesity include shortness of breath, 
chest tightness, and a higher risk of gastroesoph‑
ageal reflux (FIGURE 1).9
However, the spectrum of clinical coexistence 
of obesity and asthma is much wider and not lim‑
ited to the non ‑type 2 disease developing in adults 
in the form of the “classic” phenotype of obesity‑
‑associated asthma. These complex issues are dis‑
cussed in the present review. In addition, consid‑
ering that our knowledge on interactions between 
obesity and asthma has substantially increased 
in the last few years, we describe some potential 
underlying mechanisms, with a special focus on 
the functional effects of obesity on asthma.
Obesity and asthma General clinical picture and 
pathophysiology Overweight (body mass index 
[BMI] ≥25 kg/m2) and obesity (BMI ≥30 kg/m2) 
constitute a growing health problem in many 
parts of the world, and are associated with an in‑
creased risk of chronic noncommunicable diseas‑
es, such as type 2 diabetes mellitus and cardiovas‑
cular disorders.21 Overweight has been reported 
FIGURE 2 Schematic 
overview of the effects 
of obesity on 
the development 
of asthma
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• Systemic Inflammation
• Insulin resistance/diabetes 
• Dyslipidemia
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• High blood pressure 
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• Sedentary lifestyle
• Unhealthy diet
• Genetic susceptibility
• Epigenetic changes
• Hormonal disturbances
• Drugs (side effects) 
Asthma
• Coughing
• Wheezing
• Shortness of breath   
• Decreased lung function  
• More air trapping 
•Th1-biased responses
?
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reported.32 Interestingly, asthma rescue medica‑
tion treatment proved to reduce the risk of obe‑
sity, which was independent of physical activity 
or the use of other asthma medications.32
The childhood phenotype of asthma associ‑
ated with obesity should possibly be differenti‑
ated from late ‑onset obesity ‑associated asthma 
typically observed in adult women (and concise‑
ly characterized in FIGURE 1).28 This classic obesity‑
‑associated asthma is usually severe, whereas 
asthma accompanying obesity in children is dif‑
ficult to treat or poorly controlled rather than se‑
vere.31 Children with this phenotype are usual‑
ly nonatopic, have an early ‑life weight gain and 
asthma ‑like symptoms, as well as impaired lung 
growth and altered airflow perception as putative 
underlying mechanisms.28 On the other hand, it 
cannot be excluded that a substantial percentage 
of obese asthma patients are children who origi‑
nally have type 2 ‑driven asthma, with subsequent 
development of obesity due to other factors.28 
Interestingly, even atopic children with asthma 
have been described to exhibit Th1 polarization 
if obesity with high levels of leptin is simultane‑
ously present.33 Similarly to adults, the underly‑
ing mechanisms explaining the relationship be‑
tween asthma and obesity in children are still 
poorly understood.
Sex differences The distinct non–type 2 ‑driven 
phenotype of obesity ‑associated asthma is seen 
primarily in women, which is one of the major 
not late ‑onset asthmatics, BMI increased with 
longer disease duration.25 The understanding of 
the mechanisms and classification of the subtypes 
of asthma associated with obesity seems even 
more complex. Obesity skews CD4+ cells towards 
Th1 polarization and can complicate the classic 
atopic type 2 immune response by altering eo‑
sinophilic inflammation.29 This does not mean, 
however, that obesity never coincides with atopic 
asthma, because there are also patients who show 
airway inflammation with fewer neutrophils but 
more macrophages compared with obese patients 
with nonatopic asthma.30 More human studies, 
preferably in combination with more mechanis‑
tic investigations in animal models, are required 
to better understand the complex mechanisms 
of the interaction between lean/obese fat tissue 
and allergic/nonallergic airway inflammation.
Obesity and asthma in children The age of onset 
affects the clinical picture of asthma not only in 
adults16,25 but also in children. However, the re‑
lationship between obesity and the age of asth‑
ma onset is possibly even more complex, with 
a more causal role of obesity in the case of lat‑
er age of onset and with obesity being more of 
an asthma comorbidity in the case of earlier on‑
set.16 Furthermore, to make things even more 
complex, although several studies demonstrat‑
ed obesity to be a risk factor of pediatric asth‑
ma,31 the opposite effect with childhood asth‑
ma increasing the risk of obesity has also been 
Balanced (low)
inflammatory adipokines
leptin, resistin, lipocalin 2
IL-6, TNF-α, IL-1β, IFN-γ 
Balanced (high)
anti-inflammatory adipokines
adiponectin, ghrelin 
IL-4, IL-10
Lean adipose tissue
High 
inflammatory adipokines 
leptin, resistin, lipocalin 2
IL-6, TNF-α, IL-1β, IFN-γ
Low
anti-inflammatory adipokines
adiponectin, ghrelin  
IL-4, IL-10
Obese adipose tissue
Normal immunometabolic function
Balanced inflammation, insulin sensitivity
Immunometabolic dysfunction
Systemic inflammation, insulin resistance
FIGURE 3 Effects of 
obesity on adipokine 
production and their major 
immunometabolic 
consequences. This figure 
is based on several 
previously published 
images, especially those 
by Makki et al89 and 
Liddle et al.90 
Abbreviations: IFN ‑γ, 
interferon γ; TNF ‑α, tumor 
necrosis factor α; others, 
see FIGURE 1
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increased CD4+ T ‑cell immunity and activation of 
mast cells, as well as activation of transcription 
factors such as NF ‑κB. It is not surprising that 
leptin may contribute to asthma development or 
increase its severity in obese individuals.42
Resistin is another hormone produced by adi‑
pose tissue. It interferes with insulin by modify‑
ing insulin sensitivity. Resistin levels are increased 
in obese patients and lead to insulin resistance 
(resistin was originally named for its resistance 
to insulin).47 It further triggers the activation of 
NF ‑κB and production of cytokines, thereby pro‑
moting proinflammatory effects,48 which in turn 
are thought to contribute to more severe exacer‑
bations of asthma in obese patients.49
Ghrelin is another important appetite hormone 
involved in metabolism and energy balance.50 It 
is responsible for increased food intake and de‑
creased fat utilization.51 Furthermore, ghrelin 
can inhibit the expression of the proinflammato‑
ry cytokines IL ‑1β, IL ‑6, and TNF ‑α.52 However, 
in obese individuals, ghrelin levels are decreased, 
which is thought to be a physiological protective 
mechanism regulating energy balance.53
Adipokines exert significant effects not only 
on metabolism but also on the immune system, 
and, although detailed mechanisms of their con‑
tribution still need to be established, they seem 
to represent important mediators in obesity‑
‑associated asthma.
Genetics Although our knowledge on the ge‑
netic background of the links connecting obe‑
sity and asthma is limited among other reasons 
due to the polygenic character of both conditions, 
heredity definitely represents another aspect im‑
portant for understanding the relationships be‑
tween asthma and obesity.54,55 The analysis of 
gene expression, the results of which are strongly 
dependent on the genetic background, is already 
a well ‑established diagnostic method in oncology 
and hematology. Moreover, in the near future, it 
might become useful also in allergology, where it 
could help differentiate between various asthma 
pheno‑ or endotypes on the molecular level (so 
called molecular phenotyping) making it possi‑
ble to specifically apply an effective treatment.3,56
It has been shown that the genotype is a more 
stable parameter for the prediction of biological 
characteristics of asthma than the family histo‑
ry. A negative background in the family history 
accompanied by a high genotypic risk has been 
observed not only in asthma but also in obesi‑
ty.57 Furthermore, Hallstand et al58 found that 
obesity shares a substantial portion of its genet‑
ic components with asthma. In addition, genetic 
links between blood lipid metabolism and aller‑
gic mechanisms have been reported on the mo‑
lecular level.59,60
Several susceptibility loci have been identified 
that are shared between asthma and obesity, for 
example, adrenoceptor β2 gene (ADRB2), nuclear 
receptor subfamily 3 group C member 1 (NR3C1), 
and TNF ‑α gene (TNF) (TABLE).54,61‑63 Adrenoceptor 
characteristics of this phenotype.3,9 Some addi‑
tional sex ‑specific interactions between obesity 
and asthma have been described. For example, in 
a longitudinal study, obesity was found to increase 
the risk of asthma in Canadian women but not in 
men.34 Furthermore, asthma severity was found 
to be robustly associated with BMI only in wom‑
en, which was additionally affected by the hor‑
monal status, as determined by early menarche.35 
Likewise, obesity was not associated with AHR in 
men, while such an effect was observed in wom‑
en with moderate AHR.36 In another study, sex 
had no effects on obesity ‑asthma association in 
children, but trunk predominant (central) adipos‑
ity was significantly associated with asthma only 
among women.37 Overall, epidemiological stud‑
ies suggest that the effects of obesity on asthma 
are greater in women, which seems to be related 
to the activity of estrogens.35,38
Adipokines Through its endocrine function re‑
flected by the production of adipokines and pos‑
sibly some other factors, adipose tissue influenc‑
es the immune and metabolic responses.39 Adi‑
pokines are peptide substances produced by ad‑
ipose tissue; they have the properties of classic 
cytokines, chemokines, and hormones.40
Adiponectin is the most abundant adipokine 
in the adipose tissue, responsible for regulating 
the energy balance by, for example, stimulation 
of insulin secretion or increasing fatty acid oxida‑
tion.41 It has anti ‑inflammatory effects, mediated 
by the stimulation of IL ‑10 synthesis and endoge‑
nous IL‑1 receptor antagonist production, as well 
as by the inhibition of nuclear factor κB (NF ‑κB) 
signaling, expansion of vascular smooth muscle 
cells, and expression of adhesion molecule.42 In 
addition, adiponectin further suppresses the pro‑
inflammatory effects by inhibiting IL ‑6 and TNF‑
‑α.40 The concentrations of adiponectin are high‑
er in women than in men. This difference arises 
after puberty as the adiponectin synthesis is in‑
hibited by testosterone.43 In obese patients, ad‑
iponectin levels are reduced; therefore, its anti‑
‑inflammatory effects are missing, which might 
contribute to increased inflammation present in 
obesity ‑associated asthma.44
Another important mediator produced by ad‑
ipose tissue is leptin, a hormone that regulates 
energy balance and appetite. Leptin is transport‑
ed into the brain, where it binds to its receptor 
in the hypothalamus. This results in activation 
of the Janus kinase ‑signal transducer and activa‑
tor of transcription protein (JAK ‑STAT3) signal‑
ing pathway, which further changes the produc‑
tion of certain peptides, thus reducing food in‑
take.45 A higher proportion of the adipose tissue 
in the overall body mass in obese patients leads 
to an increase in leptin levels. Furthermore, over‑
weight and obese individuals may develop leptin 
resistance, which causes weight gain due to in‑
creased hunger.46 Leptin exerts also immuno‑
modulatory effects of the proinflammatory type, 
including increased IFN ‑γ–mediated responses, 
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legumes, or vegetables seems to decrease the risk 
of disease development in the offspring. Like‑
wise, a wrong prenatal and early ‑life diet results 
in increased risk of obesity and metabolic dis‑
eases.11,26,70 Nutritional status of the newborn, 
reflected by birthweight, has been shown to af‑
fect the risk of obesity or asthma in adulthood.26
In an epigenome ‑wide analysis, Rastogi et 
al71 studied peripheral blood mononuclear cells 
obtained from obese children with asthma and 
showed a decreased promoter DNA methyla‑
tion of the genes encoding molecules involved 
in innate immune responses or nonatopic in‑
flammation, such as C ‑C motif chemokine ligand 
5 (CCL5, chromosome 17q12), interleukin 2 re‑
ceptor α (IL2RA, chromosome 10p15.1) or T ‑box 
21 (TBX21, chromosome 17q21.32). At the same 
time, they observed increased levels of promot‑
er methylation of the low ‑affinity receptor for 
IgE (Fc fragment of IgE receptor II; CD23) gene 
(FCER2, chromosome 19p13.2), and transform‑
ing growth factor β1 gene (TGFB1, chromosome 
19q13.2), the latter controlling T ‑cell immunity 
responses.71 However, to the best of our knowl‑
edge, the study by Rastogi et al71 is the one and 
only analyzing differential epigenetic patterns in 
asthma associated with obesity.11,65,66
Insights from mouse models Studies in animals 
provide research options not available in hu‑
mans. In particular, in ‑depth investigations of 
the disease ‑underlying mechanisms are possible. 
β2 affects the activity of the sympathetic ner‑
vous system, which has an effect on respiration 
and systemic metabolism.38 In turn the glucocor‑
ticoid receptor encoded by NR3C1 modulates in‑
flammation, a crucial component of both obesi‑
ty and asthma, while TNF ‑α stimulates immuni‑
ty and inflammation, which are crucial elements 
of the mechanisms underlying both conditions.38 
Several loci, including ADRB2, TNF, LTA4H, GN-
PDA2, and ROBO1, have been found to be associ‑
ated with asthma and obesity in children, some‑
times on the genome ‑wide level (TABLE 1).63,64
Epigenetics Both asthma and obesity are typi‑
cal conditions determined by the interactions be‑
tween genetic background and environmental in‑
fluences, the latter mediated by epigenetic mech‑
anisms.11,65‑69 Epigenetic modifications function‑
ally alter the genome and thus gene expression 
without changes in the DNA nucleotide sequence. 
DNA methylation and histone marks, such as 
methylation, acetylation, phosphorylation, and 
others, represent classic epigenetic mechanisms. 
However, the extended definition of epigenetics 
includes also other regulatory mechanisms, for 
example, those mediated by microRNAs.11,65,66
Prenatal and early ‑life environmental expo‑
sures are known to epigenetically affect the risk 
of asthma and obesity.11,26,70 For instance, in ute‑
ro or early childhood exposure to cigarette smoke 
or traffic pollutants increases the risk of asthma, 
whereas the proper maternal diet containing fish, 
TABLE 1 Overview of susceptibility loci shared between obesity and asthma54,61‑63,88
Gene Main function
Adrenoceptor β2
(ADRB2; chromosome 5q32)
Catecholamine receptor, expressed in various tissues (eg, 
respiratory tract)
Nuclear receptor subfamily 3 group C member 1
(NR3C1; chromosome 5q31.3)
Glucocorticoid receptor; regulation of transcription of 
glucocorticoid ‑responsive genes, such as those involved in 
metabolism or immune responses
Major histocompatibility complex
(HLA ‑DRB1, chromosome 6p21.32)
Human leukocyte antigen gene cluster; central role in 
the immune system
Insulin‑like growth factor 1
(IGF1; chromosome 12q23.2)
Essential factor for the regulation of cell growth
Interleukin 1α
(IL1A; chromosome 2q14.1)
Pleiotropic cytokine involved in regulation of various immune 
responses
Leptin
(LEP; chromosome 7q32.1)
Regulation of energy balance
Leukotriene A4 hydrolase
(LTA4H; chromosome 12q23.1)
Enzyme catalyzing the final step of leukotriene B4 biosynthesis
Protein kinase Cα
(PRKCA; chromosome 17q24.2)
Involved in diverse cellular signaling pathways, such as cell 
adhesion and transformation
Tumor necrosis factor α
(TNF; chromosome 6p21.33)
Multifunctional proinflammatory cytokine
Vitamin D receptor gene
(VDR; chromosome 12q13.11)
Transcription factor involved in metabolic pathways (eg, 
calcium homeostasis)
Glucosamine ‑6‑phosphate deaminase 2
(GNPDA2; chromosome 4p12)
Enzyme participating in aminosugar metabolism
Roundabout guidance receptor 1
(ROBO1; chromosome 3p12.3)
Involved in the development of the nervous system
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interaction between asthma and obesity in both 
human cohorts and animal models are required.
The importance of some rather specific fac‑
tors, potentially contributing to the interplay 
between obesity and asthma, has also been in‑
vestigated in mouse studies. One study conduct‑
ed in the HFD ‑OVA mouse model of obese asth‑
ma demonstrated higher AHR, airway inflamma‑
tion, and proinflammatory cytokine levels. In‑
terestingly, when compared with nonobese con‑
trols without asthma, vitamin D levels were lower 
in asthma ‑alone and obesity ‑alone groups and 
the lowest in obese mice with asthma, suggest‑
ing a link between vitamin D and inflammation 
in allergic airway inflammation.80 Excessive di‑
etary intake of saturated fatty acids, the nutri‑
tional factor also abundantly present in experi‑
mental HFD,81 has been found to be a risk factor 
for obesity ‑related immunometabolic disorders, 
such as insulin resistance, type 2 diabetes melli‑
tus, or cardiovascular diseases.82,83 HFD ‑fed mice 
subsequently subjected to the HDM ‑based asth‑
ma model had augmented neutrophilic airway in‑
flammation and AHR accompanied by increased 
levels of IL ‑17A and macrophage inflammatory 
protein 2 (MIP2).84 Similar effects on airway in‑
flammation were observed when the HDM model 
was combined with direct treatment with palmit‑
ic acid, the main saturated fatty acid component 
of HFD. Furthermore, production of proinflam‑
matory cytokines and chemokines, such as TNF‑
‑α and IL ‑1β, MIP2, and/or monocyte chemoat‑
tractant protein 1 was upregulated.84
Summary Asthma associated with obesity rep‑
resents an  increasing health problem world‑
wide. The presence of obesity can make the clin‑
ical course of asthma more severe and more dif‑
ficult to treat, while dietary weight loss inter‑
ventions or bariatric surgery lead in obese asth‑
matics to improvements in disease control and 
lung function.29,85,86 Obesity can also contribute 
to asthma development. A specific phenotype of 
obesity ‑associated asthma has been described 
that is characterized by the presence of severe, 
late ‑onset, non –type 2 ‑driven asthma (mostly) 
in women. However, it is definitely not the only 
combination of asthma and obesity observed in 
clinical practice, although the other disease enti‑
ties are not as distinct. Obesity is associated with 
asthma or precedes its development also in chil‑
dren and men. Moreover, obesity tends to skew 
the adaptive immune responses towards Th1, but 
combinations between atopic asthma and obesi‑
ty also occur.
A substantial progress in our understanding of 
the relationships between obesity and asthma has 
been made in recent years. However, the mech‑
anistic links between these conditions are still 
poorly understood and further research is re‑
quired, especially on the basic cellular and mo‑
lecular levels. The lung may be even considered 
as an independent metabolic organ, specifical‑
ly responding to obesity and obesogenic diets.87 
Although human diseases are only modelled in 
animals and not every result obtained in these 
settings can directly be translated into real pa‑
tient situation, some of those models seem to 
well reflect disorders in humans, for example, 
mouse models of airway inflammation mimick‑
ing different mechanistic types of asthma, such 
as Th2, Th1‑/Th17 (non –Th2), and mixed (Th2/
Th1/Th17) asthma.72 Mouse models mimicking 
human asthma are based on the application of 
immune response ‑inducing substance, such as 
ovalbumin (OVA) or HDM. The resulting type of 
immunity depends on several factors, especially 
the way and timing of immunogen administra‑
tion.72 Obesity in turn can be induced in mice us‑
ing a high ‑fat diet (HFD) and/or through modifi‑
cation of the genetic background, such as leptin 
(LEP)‑, leptin ‑receptor‑ (LEPR), or proopiomela‑
nocortin (POMC)‑knockout73 (to simplify the ge‑
netic nomenclature, we do not distinguish be‑
tween human and mice genes and the names 
of human counterparts are always provided). 
The overall genetic effect of the experimentally 
used strain also contributes, sometimes differ‑
entially, to the predisposition to “asthma” (eg, 
BALB/c mice are prone to develop Th2 responses, 
while C57BL/6 mice, to non –Th2 responses)74 or 
“obesity” (eg, obesity ‑susceptible AKR mice).75,76
Studies in mouse models simultaneously mim‑
icking human asthma and obesity have generated 
several interesting findings. It has been observed 
that mice with HFD ‑induced obesity subjected 
subsequently to OVA model of allergic airway in‑
flammation showed higher levels of TNF ‑α, IL‑
‑5, and IL ‑10 in bronchoalveolar lavage fluid than 
their lean counterparts. At the same time, initial‑
ly lower eosinophil levels in bronchoalveolar la‑
vage fluid later increased due to eosinophil traf‑
ficking from the bone marrow to lung tissues.77 
Obesity ‑susceptible AKR mice fed with HFD dem‑
onstrated after OVA ‑induced allergic airway in‑
flammation model an increased susceptibility to 
allergic sensitization as compared with animals 
on a low ‑fat diet. Serum anti–OVA IgE antibod‑
ies and airway eosinophilia correlated positive‑
ly with body weight.75 Another study indicated 
that ILC2s and ILC3s are involved in the mecha‑
nisms by which HFD ‑induced obesity exacerbates 
allergic airway inflammation triggered in mice by 
means of HDM application.78 The results by Sil‑
va et al,79 obtained in a model involving HFD‑
‑induced obesity and OVA ‑induced allergic air‑
way inflammation, suggested in turn that air‑
way inflammation is affected by obesity through 
mechanisms mediated by mast cells, thymic stro‑
mal lymphopoietin, and IL ‑25, and favoring a de‑
layed immune response characterized by an exac‑
erbated Th1, Th2, and Th17 profile. Interesting‑
ly, while observations in humans suggest more 
type 1 immunity–related mechanisms underly‑
ing obesity ‑associated asthma, the picture derived 
from animal studies seems to be, at least partly, 
skewed towards type 2 immunity. Therefore, com‑
prehensive studies comparing different types of 
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Certain mediators of those effects, such as adi‑
pokines, are already known, but detailed mecha‑
nisms underlying the influences of obese fat tis‑
sue on the lung remain to be identified.
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